Hydroxyzine PRN for Long-Term Insomnia: Not Recommended
Hydroxyzine should not be used PRN for insomnia beyond 4 months, as its long-term efficacy and safety for this indication have not been established, and it is not recommended by major insomnia treatment guidelines. 1
Key Evidence Against Long-Term Use
FDA Label Limitations
The FDA label explicitly states: "The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies." 1 While this statement addresses anxiety rather than insomnia specifically, hydroxyzine is not FDA-approved for insomnia at all—it's only approved for anxiety and pruritus. Any use for sleep is off-label.
Guideline Recommendations
Major insomnia guidelines do not support hydroxyzine use:
The 2017 American Academy of Sleep Medicine guideline specifically noted that over-the-counter antihistamine sleeping aids (which includes hydroxyzine) "were not recommended due to lack of demonstrated efficacy as well as safety concerns." 2
The 2016 American College of Physicians guideline found insufficient evidence for most pharmacotherapies in chronic insomnia, with only eszopiclone, zolpidem, and suvorexant showing short-term benefit 3
Both guidelines emphasize cognitive-behavioral therapy for insomnia (CBT-I) as first-line treatment 2, 3
Safety Concerns for Extended Use
Cardiovascular Risks
Hydroxyzine carries significant warnings that become more concerning with prolonged use:
- QT prolongation and Torsade de Pointes have been reported, particularly in patients with pre-existing heart disease, electrolyte imbalances, or concurrent use of other QT-prolonging medications 1
- Use caution in elderly patients who may have undiagnosed cardiac conditions
Anticholinergic Effects
- Dry mouth is the most common side effect 4
- Cognitive impairment and confusion, especially in elderly patients 1
- The FDA specifically warns that "sedating drugs may cause confusion and over sedation in the elderly" 1
Other Risks
- Acute Generalized Exanthematous Pustulosis (AGEP), a serious skin reaction 1
- CNS depression and impaired driving ability 1
- Tolerance development (though not well-studied for hydroxyzine specifically)
Limited Efficacy Data
The 2023 systematic review examining hydroxyzine for sleep found only 5 studies with 207 total patients, showing mixed efficacy across sleep measures 4. Critically, these were all short-term studies. The review concluded hydroxyzine "could be considered as a short-term treatment option" and emphasized that "additional long-term studies with an active comparator are needed" 4.
Clinical Algorithm for Your Situation
If you've been using hydroxyzine PRN for sleep approaching 6 months:
Reassess the diagnosis: Is this truly chronic insomnia (≥3 nights/week for ≥3 months)? 2, 3
Initiate CBT-I: This is the evidence-based first-line treatment with durable benefits 2, 3
If pharmacotherapy is needed beyond 4 months:
Taper hydroxyzine: No specific taper protocol exists, but gradual discontinuation is prudent given its CNS effects
Common Pitfalls to Avoid
- Don't assume "PRN" use makes long-term hydroxyzine safer—the lack of long-term safety data applies regardless of dosing frequency
- Don't continue hydroxyzine in elderly patients without careful monitoring for cognitive effects and falls risk 1
- Don't use hydroxyzine in patients with cardiac risk factors without ECG screening and electrolyte monitoring 1
- Don't ignore the opportunity for CBT-I, which has superior long-term outcomes without medication risks 2, 3
The bottom line: Hydroxyzine lacks evidence for efficacy or safety beyond 4 months and is not guideline-recommended for insomnia. Transition to evidence-based treatments (CBT-I first, then FDA-approved hypnotics if needed) rather than continuing hydroxyzine for 6-12 months.